Rapport Therapeutics, Inc. (NASDAQ:RAPP) Financings
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Closed: US$10M raised · US$25.05 a share | Nov 4, 2026 |
| Public offering of common stock and pre-funded warrants Closed: US$175M raised · US$21 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), BTIG (co-lead), Citizens Capital Markets (co-lead) Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes | Nov 2, 2026 |
| 2.25% convertible senior notes due 2032 Closed: US$172.5M raised · Morgan Stanley +2 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead) Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes | Nov 2, 2026 |
| Private placement of common stock Closed: US$30M raised · US$21 a share · Morgan Stanley +2 Dealers: Morgan Stanley, Leerink Partners, Evercore ISI Use of proceeds: Fund clinical trials of RAP-219, other research and development, working capital and general corporate purposes | Nov 2, 2026 |
| Public offering of common stock Update: about US$250M · US$26 a share · Goldman Sachs & Co. LLC +3 Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Stifel (co-lead) | Sep 9, 2025 |